Premier, Inc. (PINC) announced a national group purchasing organization (GPO) agreement with Wilcrest Pharmaceuticals, Inc., effective April 1, 2026. The deal allows Premier members to access special pricing and terms for hazardous sterile and non‑sterile compounded preparations that Wilcrest will supply under the agreement.
The partnership gives Premier’s hospital and health‑system members a new class of compounded medications, including oncology and drug‑shortage solutions. Wilcrest, a Houston‑based FDA‑registered 503B outsourcing facility, specializes in hazardous compounding and has a track record of addressing shortages that can limit patient access to critical therapies.
Strategically, the agreement expands Premier’s supplier portfolio and strengthens its technology‑driven healthcare improvement model. By adding Wilcrest to its network, Premier can offer members broader medication options while leveraging its data‑enabled services to manage supply‑chain risk and cost. The deal is expected to enhance member value and generate additional administrative fee revenue as Premier continues to grow its GPO and performance‑services segments.
Premier’s recent financial performance provides context for the significance of the agreement. In Q4 2025, the company beat earnings and revenue estimates but issued cautious guidance for FY 2026, reflecting a transitional year in which adjusted EBITDA is guided down about 7% at the midpoint. In Q1 FY 2026, revenue and profitability slightly exceeded expectations, and management reaffirmed FY 2025 guidance. The new Wilcrest partnership is positioned to support Premier’s goal of returning to positive growth in FY 2027 by adding a new revenue stream and reinforcing its core GPO business.
A.J. Day, CEO of Wilcrest Pharmaceuticals, said, "This partnership marks a milestone for Wilcrest as we become a contracted supplier with Premier, and we aim to facilitate patient access to therapies." While Premier’s CEO has previously highlighted the company’s focus on reinvigorating performance services, no new Premier executive comment was provided for this announcement.
The agreement comes amid ongoing industry drug shortages and a broader push for cost containment. Premier’s role as a GPO that combines supply‑chain expertise with data‑enabled services positions it to address these challenges, and the addition of Wilcrest’s compounding capabilities aligns with the company’s strategy to expand its service offerings and strengthen its competitive position as it moves toward acquisition by Patient Square Capital.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.